Roche NimbleGen Q3 Sales Rise 22 Percent on Rising Sequence Capture, Array CGH Demand

According to a company spokesperson, the growth was primarily driven across the two application areas by sales of its SeqCap EZ Exome offering for target enrichment as well as its CGX cytogenetic arrays.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.